GOING BEYOND THE CONVENTIONALPOLARx™: Setting a new standard in cryoablation
Discover results from POLARx™ clinical trials that highlight the benefits of a new cryoablation system
POLARICE – 399 AF patients AF registry
In a real-world setting, PVI with POLARx™ was safe, efficient and effective in experienced cryoballoon centers
Provide real-world data on the use of the POLARx™ Cryoablation System for the treatment of atrial fibrillation
POLAR ICE (NCT04250714)
- 19 centers
- 399 patients
Primary Safety Event Rate
No Patients Suffered From:
Atrial Esophageal Fistula
Pulmonary Vein Stenosis
Mean Procedure Time (min)
Mean LA Dwell Time (min)
Mean Fluoroscopy Time (min)
Performance and Biophysical Characteristics
Single Shot Success
Mean Cryoablations per PV
Grade 3-4 Occlusion
Mean Nadir Temp (°C)
Mean Time to Isolation (sec)
Acute procedural characteristics, efficacy, and safety of a novel cryoballoon for the treatment of paroxysmal atrial fibrillation: Results from the POLAR-ICE study, Tilz et al.
CHARISMA – 10-Month Follow- Up Data
prospective , non randomize, multicenter Italian registry to assess safety and effectiveness of POLARx™ cyoablation system (112 patients, 439 PVs)
Novel cryo-balloon technology for a successful pulmonary vein isolation: acute outcome and follow-up from a large multicenter Italian clinical setting, Fassini et al
12-Month Follow-Up Data – Martin et al.
non-randomized, prospective, multicentre study enrolling 58 consecutive patients to evaluate the long-term safety and efficacy of this novel POLARx™ cyoablation system in treating Paroxismal AF. (58 patients, 231 PVs)
Novel cryoballoon to isolate pulmonary veins in patients with paroxysmal atrial fibrillation: long‑term outcomes in a multicentre clinical study, Martin et al.
Biophysical parameters to predict acute PVI
Iacopino et al
Prospective, single-arm, multicenter study, first 69 patients treated with POLARx™ Cryoablation System. Procedural and acute data was collected on 247 PVs.
Key characteristics for effective acute pulmonary vein isolation when using a novel cryoballoon technology: insights from the CHARISMA registry, Iacopino et at.
Yap et al
Prospective cohort study, multicenter study, 110 consecutive patients who underwent first‐time cryoballoon ablation (POLARx™: n = 57; AFA‐Pro™: n = 53).
Comparison of procedural efficacy and biophysical parameters between two competing cryoballoon technologies for pulmonary vein isolation: Insights from an initial multicenter experience, Yap et al
Martin et al
Prospective, non-randomized, multicenter (international) registry (NCT04250714), enrolled 399 patients across 19 centers, between Aug 2020 and May 2021. This study included any patients indicated for treatment of PAF with the POLARx™ cryoablation system.
Biophysical Parameters and Time To Isolation of Pulmonary Veins with a Novel Cryoballoon: Results of POLAR ICE Study, Martin et al.
CE MARK DATA
Non-randomized, single-arm, prospective, multicenter study to assess safety and effectiveness of POLARxTM cryoablation system in patients undergoing PVI (n=30) for the treatment of paroxysmal AF.
Acute safety, efficacy, and advantages of a novel cryoballoon ablation system for pulmonary vein isolation in patients with paroxysmal atrial fibrillation: initial clinical experience, Ante et al. Multicenter1